Professor Awad’s work is supported by the prestigious American Heart Association Career Development Award, which provides $231,000 in funding over three years. His project distinguished itself in the highly competitive national landscape, ranking in the fourth percentile for its novel approach and potential impact. This validation highlights the pressing need to elucidate the mechanisms linking cardiovascular dysfunction to skeletal muscle deterioration as individuals age.

Prevailing studies have traditionally examined sarcopenia, heart failure, and cardiovascular disease as separate entities. However, Awad challenges this fragmented perspective by emphasizing the body’s integrated systems. He argues that the human organism functions as an interconnected whole rather than isolated parts. Understanding how cardiac and muscular systems co-evolve during aging could transform diagnostic and therapeutic strategies in geriatric medicine.

The central thesis of Awad’s research underlines a metabolic crosstalk between the heart and skeletal muscles, which may drive parallel declines in function. By identifying molecular and physiological correlates that unify these conditions, his team hopes to pinpoint early biomarkers that signify onset before overt symptoms manifest. Such biomarkers could revolutionize early detection, enabling interventions that forestall or reverse cardio-sarcopenia’s progression.

A distinct feature of Awad’s methodology is its foundation in engineering principles. His background in this field fosters a systems-level appreciation of biological complexity, moving beyond conventional biomedical approaches. One such tool leveraged in initial studies is Raman spectroscopy, a highly sensitive technique that detects molecular signatures within tissues by analyzing vibrational energy shifts of molecular bonds.

Through Raman spectroscopy, Awad’s group identified a unique molecular fingerprint in aging skeletal muscle—one that had eluded detection by standard methods. This fingerprint potentially signals early biochemical changes tied to muscle degradation, providing a promising lead for further investigation. This interdisciplinary viewpoint exemplifies how engineering and medical sciences can converge to yield new insights into age-related pathologies.

Collaboration lies at the heart of this research initiative. Awad is working alongside distinguished UTA colleagues such as Marco Brotto, director of the Bone-Muscle Research Center; Michael Nelson, who oversees the Clinical Imaging Research Center and the Arlington Study of Healthy Aging (ASHA); as well as experts in cellular signaling and neurocardiovascular control. These partnerships ensure a comprehensive examination of cardio-sarcopenia from molecular to systemic levels.

The ASHA study, in particular, offers a rich repository of human data pivotal for validating hypotheses generated through molecular investigations. By integrating clinical imaging and physiological assessments from diverse aging populations, Awad’s team can correlate molecular biomarkers with functional outcomes. This multilayered data synergy enhances the study’s robustness and translational potential.

Ultimately, Awad envisions that unraveling the cause-and-effect relationships underlying cardio-sarcopenia will pave the way for personalized medicine tailored to older adults. Identifying mechanistic pathways linking heart dysfunction and muscle decline could inform targeted therapies, customizing treatment protocols to individual metabolic profiles. This approach contrasts with the current generic paradigms that often neglect systemic interdependencies.

The research program officially commenced on April 1 and is poised to make significant contributions to understanding how aging orchestrates integrated physiological decline. By combining cutting-edge spectroscopy, advanced imaging, and integrative biological analysis, it aspires to shift clinical practice toward earlier diagnosis and more effective intervention strategies for cardiovascular and muscular disorders in elderly populations.

This endeavor embodies a paradigm shift in gerontology and cardiovascular research, underscoring the importance of interdisciplinary approaches to human health. The discovery of novel biomarkers and therapeutic targets linked to cardio-sarcopenia not only enhances scientific knowledge but also offers hope for mitigating some of the most debilitating aspects of aging, potentially extending healthy lifespan and quality of life.

In a broader context, Awad’s research reflects a transformative trend in biomedical engineering and translational medicine where hybrid expertise unlocks previously inaccessible questions. His work encapsulates the essential role that novel technological applications, grounded in engineering principles, play in redefining how complex biological systems are understood and treated in the era of precision health.

Subject of Research: Cardio-sarcopenia—the integrated decline of heart and skeletal muscle health in aging adults.

Article Title: Researchers Investigate the Molecular Nexus Between Cardiac Dysfunction and Muscle Decline in Aging

News Publication Date: April 1, 2024

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/256a2220-e2ac-4f30-8154-a4db9a28cd1b/Rendition/low-res/Content/Public

Image Credits: UT Arlington

Keywords: Cardio-sarcopenia, aging, heart health, sarcopenia, skeletal muscle, Raman spectroscopy, biomarkers, cardiovascular disease, biomedical engineering, aging biomarkers, molecular fingerprint, personalized medicine

Chronic diseases exacerbated by poor nutrition—including cardiovascular disease, Type 2 diabetes, and obesity—continue to dominate the health landscape, accounting for an overwhelming 90% of the $4.5 trillion annual expenditure on U.S. healthcare. This alarming economic and health impact underscores the urgent need for innovative solutions that transcend conventional pharmacological approaches. The Health Care by Food™ initiative aims to rigorously examine how medically tailored nutrition can serve as an effective therapeutic modality, potentially altering disease trajectories and improving patient outcomes.

The recent wave of funding supports the development of detailed clinical trial protocols that will serve as the foundation for future large-scale randomized controlled trials. These planning grants enable investigators to meticulously design interventions that encompass produce prescriptions, medically tailored groceries, and prepared meals. Central to this research is understanding the mechanisms by which dietary modifications influence disease progression, metabolic parameters, and overall health status in populations with chronic conditions.

Kevin Volpp, M.D., Ph.D., who spearheads the initiative, emphasizes the critical importance of generating data that insurers can rely upon when making coverage determinations. “This program is structured to pinpoint specific features of food is medicine interventions that align with payer priorities, thereby facilitating integration into healthcare reimbursement frameworks,” Volpp explains. With his background in health incentives and behavioral economics, Volpp advocates for harnessing human-centered design principles to enhance patient engagement, adherence, and retention within these programs.

One of the distinctive features of this initiative is its iterative research model which begins with small-scale, human-centered clinical trials focusing on behavioral science aspects. To date, 23 pilot trials are currently underway, each exploring various strategies to optimize program implementation and maximize therapeutic benefit. These foundational studies will generate valuable insights on patient responses and inform the design of robust, scalable interventions suitable for nationwide adoption.

Diet-related chronic diseases are multifactorial in nature, where both biological and socio-environmental factors converge. The Health Care by Food™ initiative appreciates this complexity, incorporating behavioral economics and motivational strategies that address barriers to healthy eating in vulnerable populations. The new grants allow for thorough exploration of intervention mechanisms, ranging from nutrient absorption and metabolic modulation to psychosocial determinants that influence dietary behaviors.

The anticipated large-scale randomized controlled trials will not only elucidate clinical efficacy but will also provide comprehensive cost-effectiveness analyses that are essential for policy advocacy. Such evidence is imperative for validating food as a reimbursable treatment modality, shifting the healthcare paradigm towards prevention and management through nutrition. Researchers funded by this initiative are tasked with constructing rigorous protocols that meet stringent federal funding criteria, facilitating future support from government agencies, industry, and philanthropic organizations.

Beyond the clinical and economic dimensions, Health Care by Food™ is embedded within a broader advocacy and educational framework, aimed at reshaping perceptions around nutrition in medical care. This multifaceted strategy addresses systemic health inequities by promoting equitable access to nutritious foods, thereby advancing social determinants of health. Strategic partnerships with prominent funders—including The Rockefeller Foundation, Kroger, and Kaiser Permanente—reflect a collaborative ecosystem geared towards driving innovation in chronic disease management.

As preliminary data from ongoing trials begin to emerge later this year, the medical community and policymakers alike will gain unprecedented insights into how food-based interventions can be harnessed as standardized components of treatment regimens. This evidence base will be pivotal in establishing food is medicine programs as integral, reimbursable facets of healthcare delivery, with the potential to revolutionize disease prevention and improve population health outcomes on a massive scale.

The scientific rigor underlying this initiative is evident in its commitment to employing advanced research methodologies, comprehensive behavioral assessments, and precise nutritional biochemistry. By focusing on both physiological and psychosocial outcomes, the Health Care by Food™ program exemplifies translational research that bridges bench science with clinical practice, ultimately striving to reduce the burden of cardiovascular and metabolic diseases through targeted dietary therapeutics.

In summary, the American Heart Association’s Health Care by Food™ initiative stands at the forefront of a transformative movement, seeking not merely to supplement medical care with better nutrition but to redefine the concept of treatment itself. By investing in cutting-edge clinical research, fostering interdisciplinary collaboration, and advocating for systematic policy change, the AHA is championing a future where food is recognized as a potent and reimbursable medicine in the battle against chronic disease.

Subject of Research: Integration of Nutrition-Based Interventions into Chronic Disease Management through Clinical Trial Design and Implementation

Article Title: American Heart Association Launches Major Grant Initiative to Propel “Food Is Medicine” Research into Clinical Practice

News Publication Date: May 20, 2025

Web References:

• Health Care by Food™ Initiative: https://healthcarexfood.org/
• AHA Newsroom: https://newsroom.heart.org/news/planning-grants-awarded-for-competitive-proposals-testing-efficacy-of-food-is-medicine?preview=05d2&preview_mode=True#_ftnref1
• AHA Presidential Advisory on Food Is Medicine: https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001182

References:

• Center for Disease Control. (2024, July). Fast Facts: Health and Economic Costs of Chronic Conditions. U.S. Centers for Disease Control and Prevention.

Keywords:
Health care, nutrition, food is medicine, clinical trials, chronic disease, cardiovascular disease, Type 2 diabetes, obesity, behavioral economics, medical nutrition therapy, health policy, disease prevention